A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention"
A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention"
复制标题
DOI：
10.1002/jbmr.3823
复制
发表时间：
2019-07-25
影响因子：
6.2
通讯作者：
Kiel, Douglas P.
中科院分区：
文献类型：
--
作者：
Leder, Benjamin Z.;Clarke, Bart L.;Kiel, Douglas P.
骨质疏松症对公共卫生的影响是巨大的，但这种疾病仍然诊断不足，治疗不足。2018年10月，美国国立卫生研究院（NIH）召开了一个题为“适当使用药物治疗预防骨质疏松性骨折”的预防途径（P2P）研讨会，旨在确定研究差距，建议未来的研究机会，并通过循证评估推进该领域。根据设计，P2P报告侧重于我们知识库中的“差距”。然而，不幸的是，该报告没有充分承认目前的证据，明确证明现有的骨质疏松症药物治疗的治疗效果，这有可能加剧目前骨质疏松症诊断和治疗的危机。(c)2019年美国骨与矿物质研究学会。
The public health implications of osteoporosis are enormous but the disease remains underdiagnosed and undertreated. In October 2018, the National Institutes of Health (NIH) convened a Pathways to Prevention (P2P) Workshop entitled "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention" designed to identify research gaps, suggest future research opportunities, and advance the field through an evidence-based assessment. By design, the P2P report focused on "gaps" in our knowledge base. Unfortunately, however, the report did not sufficiently acknowledge the current evidence that unequivocally demonstrates the therapeutic efficacy of existing pharmacologic therapies for osteoporosis, which has the potential to exacerbate the current crises in osteoporosis diagnosis and treatment. (c) 2019 American Society for Bone and Mineral Research.